



Published in final edited form as:

*J Neurosurg.* 2023 May 01; 138(5): 1302–1312. doi:10.3171/2022.7.JNS22585.

## Gene expression analysis during progression of malignant meningioma compared to benign meningioma

Andrea D. Maier, MD, PhD<sup>1,2</sup>, Alessandra Meddis, PhD<sup>3</sup>, Christian Mirian, MD<sup>1</sup>, Jeppe Haslund-Vinding, MD<sup>1</sup>, Jiri Bartek Jr, MD, PhD<sup>1,4,5</sup>, Sebastian M. Krog, MD<sup>6</sup>, Thi Uyen Phuong Nguyen, BMLS<sup>2</sup>, Aušrin Areškevičiūtė, PhD<sup>7</sup>, Linea C. Melchior, PhD<sup>2</sup>, Steffen Heegaard, MD, PhD<sup>2,8</sup>, Bjarne W. Kristensen, MD, PhD<sup>9,10</sup>, Tina N. Munch, MD<sup>1,11,17</sup>, Kåre Fugleholm, MD, PhD<sup>1</sup>, Morten Ziebell, MD, PhD<sup>1</sup>, David R. Raleigh, MD, PhD<sup>12,13</sup>, Frantz R. Poulsen, MD, PhD<sup>14,15</sup>, Thomas A. Gerds Dr rer nat<sup>3</sup>, Thomas Litman, PhD<sup>16</sup>, David Scheie, MD, PhD<sup>2</sup>, Tiit Mathiesen, MD, PhD<sup>1,17</sup>

<sup>1</sup>Departments of Neurosurgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>2</sup>Departments of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>3</sup>Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark

<sup>4</sup>Department of Neurosurgery, Karolinska University Hospital, Solna, Stockholm, Sweden

<sup>5</sup>Department of Clinical Neuroscience, Karolinska Institutet, Solna, Stockholm, Sweden

<sup>6</sup>Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

<sup>7</sup>Department of Pathology, Danish Reference Center for Prion Diseases, Copenhagen University Hospital, Copenhagen, Denmark

<sup>8</sup>Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>9</sup>Department of Clinical Medicine and Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark

Correspondence: Andrea D. Maier: Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. andrea.maier@regionh.dk.

### Author Contributions

Conception and design: Maier, Scheie, Mathiesen. Acquisition of data: Maier, Nguyen, Areškevičiūtė, Melchior, Heegaard, Scheie, Mathiesen. Analysis and interpretation of data: Maier, Meddis, Mirian, Haslund-Vinding, Bartek, Krog, Areškevičiūtė, Gerds, Litman, Scheie, Mathiesen. Drafting the article: Maier, Mirian, Haslund-Vinding, Bartek, Krog, Kristensen, Munch, Fugleholm, Ziebell, Raleigh, Poulsen, Gerds, Litman, Scheie, Mathiesen. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Maier. Statistical analysis: Maier, Meddis, Krog, Gerds, Litman. Administrative/technical/material support: Nguyen, Areškevičiūtė, Melchior, Heegaard, Kristensen, Ziebell, Scheie, Mathiesen. Study supervision: Bartek, Melchior, Heegaard, Kristensen, Munch, Fugleholm, Ziebell, Raleigh, Poulsen, Gerds, Litman, Scheie, Mathiesen.

### Disclosures

Dr. Heegaard: consultant for Sanofi, Leo Pharma, Santen, and Thea. Dr. Litman: funded by LEO Pharma.

### Supplemental Information

#### Online-Only Content

Supplemental material is available with the online version of the article.

*Supplementary Material.* <https://thejns.org/doi/suppl/10.3171/2022.7.JNS22585>.

<sup>10</sup>Department of Pathology, The Bartholin Institute, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>11</sup>Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

<sup>12</sup>Departments of Neurological Surgery, University of California, San Francisco, California

<sup>13</sup>Departments of Radiation Oncology, University of California, San Francisco, California

<sup>14</sup>Department of Neurosurgery, Odense University Hospital, Odense, Denmark

<sup>15</sup>Clinical Institute and BRIDGE, University of Southern Denmark, Odense, Denmark

<sup>16</sup>Departments of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

<sup>17</sup>Departments of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

## Abstract

**OBJECTIVE**—Meningioma is the most common primary intracranial neoplasm. Only 1%–3% of meningiomas are malignant according to the 2016 WHO criteria (WHO grade III). High-grade meningiomas present specific gene expression signatures indicating aggressive growth or recurrence. However, changes in gene expression and in neuroinflammatory gene expression signatures in WHO grade III meningiomas and during progression from WHO grade I or II to grade III are unknown.

**METHODS**—The authors used a NanoString targeted gene expression panel with focus on 787 genes relevant in meningioma pathology and neuroinflammatory pathways to investigate patients with grade III meningiomas treated at Rigshospitalet from 2000 to 2020 (n = 51). A temporal dimension was added to the investigation by including samples from patients' earlier grade I and II meningiomas and grade III recurrences (n = 139 meningiomas). The authors investigated changes in neuroinflammatory gene expression signatures in 1) grade I meningiomas that later transformed into grade III meningiomas, and 2) grade III meningiomas compared with nonrecurrent grade I meningiomas.

**RESULTS**—The authors' data indicate that *FOXMI*, *TOP2A*, *BIRC5*, and *MYBL2* were enriched and the HOTAIR regulatory pathway was enriched in grade III meningiomas compared with nonrecurrent grade I meningiomas. They discovered a separation of malignant and benign meningiomas based only on genes involved in microglia regulation with enrichment of *P2RY12* in grade I compared with grade III meningiomas. Interestingly, *FOXMI* was upregulated in premalignant grade I meningioma years before the grade III transformation.

**CONCLUSIONS**—The authors found gene expression changes in low-grade meningiomas that predated histological transformation to grade III meningiomas. Neuroinflammation genes distinguished grade III from grade I meningiomas.

## Keywords

malignant meningioma; gene expression; neuroinflammation; oncology

MENINGIOMAS are the most common primary intracranial neoplasms, accounting for 37% of all primary intracranial neoplasms.<sup>1</sup> Classification is based on histopathological characteristics according to the 2016 WHO Classification of Tumors of the Central Nervous System.<sup>2</sup> The recently published 2021 WHO classification<sup>3</sup> introduces the *TERT* promoter mutation<sup>4,5</sup> and *CDKN2A/B* homozygous deletion<sup>6</sup> as additional, independent criteria for a grade 3 diagnosis. The majority of meningiomas (approximately 80%) are slow-growing, indolent grade I meningiomas, but a subset of patients (1%–3%) either present with de novo grade III meningioma (patients with a primary malignant meningioma) or develop a grade III meningioma after a previous grade I or II meningioma (patients with a secondary malignant meningioma).<sup>7</sup> Grade I meningiomas may thereby be completely benign and remain benign during follow-up (herein defined as benign grade I) or recur and undergo transformation to grade II and then grade III meningioma or directly to grade III (herein defined as premalignant grade I). Despite the high morbidity and mortality following a grade III meningioma diagnosis, attempts to develop targeted, personalized adjuvant treatment options are hindered because of limited knowledge of the phenotypes, underlying molecular mechanisms, and the rarity of this disease.

Gene expression profiling has defined molecular subgroups. The most aggressive subtype was characterized by loss of the DREAM complex, a master regulator of the cell cycle.<sup>8</sup> Surprisingly, driver mutations or alterations did not differentiate subgroups of anaplastic meningiomas, while differential gene expression did.<sup>9</sup> Targeted gene expression analyses have suggested a 36-gene signature that is associated with risk of recurrence among all meningiomas.<sup>10</sup> However, several key comparisons within grade III meningiomas remain to be explored with novel therapeutic development in sight.

There is limited knowledge in transcriptional changes across multiple recurrences, particularly in premalignant grade I or II meningiomas. Moreover, the neuroinflammatory profile in meningiomas and tumor-associated macrophages (TAMs) has shown relevance only recently.<sup>11,12</sup> TAM infiltration is decreased in aggressive meningiomas characterized as molecular subgroups with specific features.<sup>13</sup> Moreover, inhibition of immunosuppressive myeloid cells attenuates meningioma growth<sup>14</sup> and aggressive meningiomas have upregulated anti-inflammatory TAMs.<sup>12,15</sup> In this context, investigation of neuroinflammation in contrasting meningioma phenotypes is warranted. We analyzed the gene expression profile in meningioma tissue from 51 patients with grade III meningiomas treated at Rigshospitalet between 2000 and 2020, including previous benign meningiomas and later grade III recurrences. The patients were matched to 51 patients with benign grade I meningiomas known to have no recurrences despite long-term follow-up (Fig. 1).

We present a targeted gene expression analysis focusing on key neuroinflammatory pathways and genes previously suggested to be involved in meningioma biology to study 1) if premalignant grade I meningiomas differ from benign grade I meningiomas that do not grade-transform or recur, 2) if neuroinflammation profiles are different between grade I and III tumors, and 3) if previously suggested molecular features of aggressive growth and recurrence can be validated.

## Methods

### Patient Population and Sample Selection

The background population included all patients treated surgically for meningioma at the Copenhagen University Hospital between March 2000 and December 2020. Fifty-one patients with grade III meningiomas were identified in the pathology database by the SNOMED code M95303. Because of recurrences, patients underwent 1–10 surgeries, and all surgical samples were identified using the Danish social security number system ( $n = 151$ ). We previously published an in-depth, granular clinical analysis of the cohort.<sup>16</sup> We retrieved paraffin-embedded samples from 139 (92%) of the 151 surgeries. Patients with secondary grade III meningiomas had undergone previous surgery for grade I and/or grade II meningiomas that later recurred as grade III. We defined grade I and II meningiomas that later progressed to grade III as “pre-malignant meningiomas.”

All meningiomas were reevaluated by a senior neuropathologist according to the 2016 WHO criteria. Patients with grade III meningiomas were matched on sex, location (skull base or non-skull base), age at diagnosis ( $\pm 5$  years), and tumor sample age ( $\pm 5$  years) with patients who had a grade I meningioma without recurrence (benign grade I meningiomas,  $n = 51$ ). Recurrence status was checked in benign controls and defined as no growth on control MRI scans for a minimum of 5 years and no new neurological symptoms during the entire follow-up time available (a minimum 5 years). In 1 case, matching on sex was not possible. For all patients, age, sex, meningioma sample age, WHO grade, number of surgeries, anatomical localization, and histological subtype were noted. Ethics approval was given by the Regional Research Ethics Committees, Capital Region of Denmark, and exemption from patient consent was granted.

### RNA Extraction and Quality

RNA was extracted from formalin-fixed paraffin-embedded tumor blocks using the RNeasy mini kit (Qiagen). All blocks had  $> 70\%$  tumor tissue present evaluated on H&E-stained slides and were generally high in tumor cell content. A Bioanalyzer 2100 with the 6000 RNA Nano assay (Agilent Technologies) was used to evaluate the concentration, quality (the percentage of RNA fragments  $> 300$  nucleotides [ $DV_{300}$ ]), and RNA integrity number (RIN) of extracted RNA. A Nanodrop spectrophotometer (Thermo Fisher Scientific) was used to validate the concentration and purity of extracted RNA (wavelength absorbance ratio A260/280). All samples had an absorbance ratio of approximately 2.0, the median RIN was 2.3 (range 1.4–5.3), and 44% of samples had a  $DV_{300} > 50\%$ . RNA input was scaled based on the  $DV_{300}$  value [ $100 \text{ ng} \times (100/DV_{300})$ ] making the input range from 200 to 350 ng in total (NanoString Inc., MAN-10050-03).

### NanoString nCounter Analyses and Normalization

The nCounter neuroinflammation panel from NanoString covering 770 genes, including 13 housekeeping genes, was used to generate RNA expression data. We customized the panel by adding 30 targets known in previous literature to be involved in meningioma pathophysiology<sup>9,17</sup> (Supplementary Material S1). RNA was hybridized with biotin-labeled capture probes for 18–19 hours at 65°C using the nCounter XT CodeSet gene expression

panel assay (NanoString Inc., MAN-10056-03). Samples were loaded to the nCounter preparation station. Excess capture probes and reporter probes were removed, and the hybridized RNA was loaded onto a cartridge and immobilized for imaging on the nCounter Digital Analyzer. Using nSolver 4.0 (NanoString Inc.), the technical success of the experiment was assessed by hybridization effectiveness and an overall quality control check. Binding density flags were present in 8 samples; these were rerun successfully at a lower input.

Run-to-run variability was normalized with 6 positive and 8 negative RNA transcripts included in the CodeSet. Sample-to-sample variability was normalized using counts from the 13 included housekeeping genes with the GeNorm Algorithm and the NanoStringNorm package in R.<sup>18</sup> RNA from one sample was run in 8 different batches to evaluate a possible batch effect.

### Statistical Analyses

Pre hoc, four key comparisons of the targeted gene expression profile were planned (Fig. 1).

In analysis 1, grade I meningiomas from benign controls were compared with meningiomas from patients with grade III meningiomas. In patients with subsequent grade III recurrences, the first grade III meningioma was used.

In analysis 2, grade I meningiomas from benign controls were compared with premalignant grade I meningiomas. Nine patients presented with a premalignant grade I meningioma and were included in the analysis. In patients with more than one premalignant grade I meningioma, the first was used.

Analysis 3 was within patients with grade III meningioma. We compared grade III meningiomas from patients with primary malignant meningioma with grade III meningiomas in patients with secondary malignant meningioma. In patients with multiple grade III recurrences, the first was used.

Analysis 4 was within patients with secondary grade III meningiomas. We compared the last premalignant meningioma (if multiple grade I or II recurrences were available) with the first grade III meningioma to investigate changes in gene expression on either side of the “grade switch.”

To investigate differences of gene expression we used a probabilistic index (PBI) regression model. In analyses 1, 2, and 3, the PBI is the probability that the gene expression in the tumor of a patient in one group is higher than the gene expression in the tumor of a patient in the other group. The regression analyses were adjusted for age at date of tumor biopsy and sex. Hence, the PBI regression model is a generalization of the Mann-Whitney-Wilcoxon rank test, which allowed us to control for patient demographics. In analysis 4 (Fig. 1), we accounted for the fact that two measurements are coming from the same individual, and we employed the Wilcoxon signed-rank test (formulas available in Supplementary Material S2); p values were adjusted using the Benjamini-Hochberg correction method. Differentially expressed genes (DEGs) based on the PBI had an adjusted p value < 0.05.

## Heatmaps and Pathway Analyses

Qlucore Omics Explorer version 3.7 (Qlucore AB) was used to generate heatmaps and 2-way unsupervised hierarchical clustering (UHCL) based on DEG identified from t-tests in analyses 1, 2, and 3. For all analyses, the following filters were applied: variance > 0.1,  $p < 0.05$ , and > 2-fold change in gene expression, except analysis 1, in which the variance filter was set to > 0.2. Analysis 1 was extended by subgrouping genes according to biofunctions relevant in neuroinflammation (e.g., microglia and cytokines) as annotated by NanoString, and by assessing heatmaps based on the genes in the respective neuroinflammatory pathway.

DEGs from t-tests in analysis 1 were loaded into Ingenuity Pathway Analysis (Qiagen),<sup>19</sup> and data were assessed in the Ingenuity Knowledge Base. For canonical pathways, a  $-\log(p \text{ value}) > 3$  and z-scores > 2 or < -2 were set as thresholds for significant activation or inhibition, respectively.

## Results

### DEGs in WHO Grade III Meningiomas and Grade I Meningiomas

An overview of patients with grade III meningiomas and benign controls can be seen in Table 1. A comparison of the 51 first grade III meningiomas and the 51 benign grade I meningiomas from controls yielded 429 DEGs based on the PBI (Fig. 2A). The top 5 upregulated genes with the highest PBI in grade III cases were *TOP2A*, *MELK*, *RAD51*, *BIRC5*, and *PTTG1*. Among benign grade I meningiomas from benign controls, the top 5 upregulated genes based on PBI were *SLC44A1*, *ENPP6*, *PINK1*, *AGO4*, and *TNFRSF25*. A heatmap and UHCL based on 78 (36 up and 42 down) DEGs, all included in the 429 DEGs identified in the PBI model (Figs. 3 and 4), showed almost complete separation of grade I and III meningiomas. We expanded the analysis and constructed heatmaps of the genes involved in the respective pathways as annotated by NanoString (Table 2). Genes involved in microglia regulation clearly separated benign grade I and grade III meningiomas (Supplementary Material S3).

Among canonical pathways (Supplementary Material S4), the biological pathway most significantly enriched (p value and z-score combined) by genes in the data set was the HOTAIR Regulatory Pathway [ $-\log(p \text{ value}) = 3.68$ , z-score = 2.24] with *EZH2*, *FOXMI*, *JAM2*, *MMP12*, and *SPPI* involved.

### Premalignant WHO Grade I Tumors Show an Aggressive Gene Expression Profile

The gene expression signature from 9 premalignant grade I meningiomas was compared with meningiomas from benign controls. A total of 37 DEGs were identified based on the PBI. The top 5 genes with the highest PBI (sorted by adjusted p value) in premalignant grade I meningiomas compared with the 51 benign grade I meningiomas were *CASP8*, *SIN3A*, *ARNT2*, *SMARCE1*, and *SETD1A*. The list also included *FOXMI* (adjusted p value = 0.014), H3-3A (adjusted p = 0.037), and *TRAF7* (adjusted p = 0.005) (Fig. 2B). The top 5 genes with the lowest PBI (sorted by adjusted p value) included *KDM1A*, *PEX14*, *HDAC1*, *PINK1*, and *PIK3CA*. UHCL and the heatmap showed 21 DEGs (Fig. 5). Consensus between the PBI model (nonparametric, generalization of Mann-Whitney-

Wilcoxon rank test) and quantification in the Qlucore software (parametric, t-test) was found in the following 7 genes: *IGF2*, *FOXM1*, *ARNT2*, *TNF*, and *SIGLEC1* (upregulated) and *PRKAR2B* and *C4A* (downregulated).

### No DEGs Identified in Secondary and Primary WHO Grade III Meningioma

A comparison of grade III meningiomas from patients with secondary (n = 24) and primary (n = 27) malignant meningioma showed no DEGs based on the PBI (Supplementary Material S5). T-tests yielded 5 DEGs, among these *MYBL2*. However, the q value was 0.51 (Supplementary Material S6). Comparison of rhabdoid/papillary and anaplastic histology (heatmap and UHCL) is shown in Supplementary Material S7.

### DEGs at Grade Switching

A comparison at grade switch within patients with secondary malignant meningioma yielded 119 DEGs. The top 5 genes (sorted by p value) with a positive median of the difference between the first grade III tumor and the last premalignant tumor, and thus upregulated, were *MYBL2*, *TOPBP1*, *PTTG1*, *RRM2*, and *NCAPH*. The top 5 genes with a negative median of the difference were *ENPP6*, *P2RY12*, *FGL2*, *CSF1R*, and *BIK* (Supplementary Material S5).

### Gene Expression Trajectories Across Recurrences

The gene expression trajectories of *FOXM1*, *TOP2A*, and *P2RY12* across recurrences among patients with malignant meningiomas are shown in Supplementary Material S8. We observed large intra- and interpatient variability across the trajectories, but a trend toward a rise in *FOXM1* and *TOP2A* expression was seen while *P2RY12* expression diminished.

## Discussion

We detected upregulation of transcripts defining a malignant phenotype already in premalignant, histological grade I meningiomas. Further analyses showed differences of neuroinflammatory gene expression profiles between grade I and III meningiomas. Our findings also corroborated previous reports that gene expression signatures in meningiomas with aggressive phenotypes are enriched for genes involved in cell-cycle regulation and mitosis.<sup>10</sup>

### Clinical Implications and Targets for Precision Medicine

Personalized follow-up and adjuvant treatment to minimize morbidity and optimize healthcare utilization could avoid unnecessary treatment and imaging. In this context, 1%–3% of all meningiomas that are histologically diagnosed as grade I meningiomas according to the WHO 2016 classification are known to undergo malignant transformation and finally recur as secondary malignant meningiomas, which carry dismal prognoses.<sup>7</sup> Early identification of this subgroup would provide a treatment window to optimize outcomes via additional surgery, closer follow-up, or adjuvant therapies. Molecular markers that define aggressive clinical courses comprise patients with loss of 1p,<sup>20</sup> *TERT* promoter mutations,<sup>4,5</sup> intermediate or malignant methylation classes,<sup>21</sup> *CDNK2A* homozygous deletion,<sup>6</sup> or high Ki-67 labeling index.<sup>22,23</sup> Only 5.4%–15% of meningiomas harbor the *TERT* promoter

mutation,<sup>4,5</sup> and < 5% harbor CDKN2A/B alterations; thus, molecular markers for improved prognostic precision are needed in the remaining cases. Our data revealed a distinctive signature of grade III meningiomas already in premalignant grade I meningiomas. Benign grade I meningiomas that remained benign could thus be differentiated from premalignant grade I meningiomas that progressed to grade III. Early identification of the latter would allow tailored adjuvant treatment and follow-up. Our findings are in line with targeted gene expression data,<sup>10</sup> and here it is indicated that changes in RNA expression can happen years before phenotypic transformation. Premalignant grade I tumors had upregulation of *FOXMI* years before malignant transformation (Figs. 2B and 5). Previously, Viaene et al. identified differences in whole-transcriptome analyses in grade I meningiomas that later progressed to grade II (n = 3 paired cases) compared with grade I meningiomas without grade progression and additionally evaluated differences in gene expression among all meningioma grades.<sup>24</sup> In comparison with our findings, they reported separate clustering of grade I progressing and grade I nonprogressing meningiomas. This supports our proof-of-concept finding that detectable changes in gene expression precede a phenotypical transformation to grade III. We did not find any direct matches between the 7 genes expressed differentially between grade I meningiomas that progressed to grade III (analysis 2) and those that did not, and those reported by Viaene et al. in their comparison of grade I progressing versus grade I nonprogressing meningiomas. In their analyses, TNF-related genes, IGF1, and SIGLEC11 were upregulated in progressing grade I meningiomas. Moreover, they compared nonpaired grade I and III meningiomas and found, as we did, upregulation of *FOXMI*, *EZH2*, *CHEK1*, *BIRC5*, *TOP2A*, and *MYBL2* in grade III meningiomas. They reported differential expression of *GREM2*, *SNORA46*, and *SNORA48* among all meningioma grades. These genes were not included in our study, which compromises comparability of these genes. Discrepancies may reflect different methodologies (full transcriptome vs targeted gene expression) and, importantly, different biological hypotheses. Viaene et al. studied progression to grade II, while we analyzed grade III meningiomas. Different transcripts may be implicated in transformation to grade II compared with grade III.

The central role of *FOXMI* in aggressive meningioma biology is not a new finding.<sup>10,17,25</sup> Our data set corroborates its high expression in a large cohort of grade III meningiomas and unprecedentedly describes its upregulation in premalignant grade I meningiomas in a unique series of meningiomas that progressed from grade I to grade III. The 2.6-fold difference of *FOXMI* expression between grade III and I meningiomas in our data might indicate *FOXMI* as a pharmacological target in humans. The *FOXMI* inhibitor Siomycin-A has been shown to diminish meningioma volume and growth in mouse models,<sup>25</sup> although inhibition is complicated by posttranslational modifications, kinetics, and clinical factors.<sup>26,27</sup> *FOXMI* inhibitors are therefore not yet available for human use, despite our data and previous data. Moreover, high expression of *CHEK1* (encoding Checkpoint kinase 1, Chk1) in grade III versus grade I meningiomas was evident in our material. Chk1 inhibitors are used either as monotherapy or in combination with genotoxic therapies in clinical and preclinical studies.<sup>28,29</sup> So far, no clinical trials have explored their use in aggressive meningioma. The potential of targeted therapy based on upregulated transcripts in benign meningioma to prevent aggressive transformation is not known, although our findings and other recent data suggest investigating transcripts such as *EZH2*, *CHEK1*, and *FOXMI* for preclinical testing.



The gene expression of *FOXMI* and *TOP2A* varied extensively across recurrences but appeared to be higher in malignant than benign tumors (Supplementary Material S8). Our study has shown that NanoString technology is suitable for gene expression studies in archived formalin-fixed paraffin-embedded meningioma tissue, as degraded RNA can be compensated through increasing input. The gene expression profiles could support screening profiles to quickly identify meningiomas at high risk of malignant transformation and allow potentially curative measures before transformation. Following prospective validation and protein analyses, upregulated transcripts could be included in a prognostic, targeted gene expression panel, and inclusion of neuroinflammatory markers could be predictive for assessing outcome of future treatment targeting protumorigenic macrophages.

### Neuroinflammatory Signatures and Two Contrasting Meningioma Phenotypes

We found differences in genes involved in microglia regulation between grade I and III meningiomas (Table 2 and Supplementary Material S3), which were in concordance with novel findings of an immunogenic meningioma subtype.<sup>13</sup> *P2RY12*<sup>30,31</sup> had a high PBI of expression in grade I tumors from benign controls. Furthermore, *P2RY12* and *CX3CR1*<sup>32</sup> had a > 1.5-fold lower expression in WHO grade III compared with benign grade I meningiomas. *P2RY12* is considered a microglia-specific marker even under pathological conditions<sup>33</sup> and is associated with the M1 proinflammatory subtype.<sup>34</sup> *CX3CR1* is a chemokine receptor for fractalkine, which is, among other features, secreted by damaged neurons to recruit microglia.<sup>31</sup> Our results suggest that migrating microglia may have a role in proimmunogenic meningiomas, although the postulated microglial specificity of *P2RY12* must be further established.

*FGL2* and *SFRP1* had a > 2-fold change in the benign grade 1 meningiomas compared with the grade 3 meningiomas. The precise antineoplastic functions of most studied genes are not known, while *FGL2*<sup>35</sup> and *SFRP1* have specified antineoplastic or proneoplastic functions. The *SFRP* family modulates Wnt-signaling and epigenetic silencing of *SFRP* leads to Wnt-pathway activation;<sup>36</sup> our results agree with earlier findings of high *SFRP1* expression in tumors with low *FOXMI* expression in meningiomas.<sup>17</sup> *FGL2* is a membrane-bound or secreted protein expressed by macrophages, T cells, and tumor cells.<sup>35</sup> In glioma, it confers poor prognosis,<sup>37</sup> and *FGL2* may promote tumor progression by expanding tumor-supportive M2-macrophages.<sup>37,38</sup> Its possible role in meningioma is, however, far from established, and *FGL2* can instead recruit inflammatory cells in other malignancies.<sup>35</sup> We did not quantify different cells, and higher *FGL2* expression could reflect large numbers of macrophages in benign meningiomas.<sup>11</sup> Moreover, the premalignant grade I meningiomas showed upregulation of *SIGLEC1*. Recently, an autoregulatory loop between cancer cells and TAMs, involving TNF-alpha and *SIGLEC1*, generated protumoral TAMs and an immunosuppressive environment in breast cancer.<sup>39</sup> Our data imply the same functional relation in meningiomas, although causality must be addressed in functional studies. Protumorigenic polarization of macrophages seems to be an early event in malignant transformation. Importantly, inhibition of the CSF1-CSF1R axis, an important regulator of macrophage phenotype, could diminish meningioma growth in a murine model.<sup>14</sup> Thus, the characterization and manipulation of protumorigenic TAMs in meningioma is pertinent for future treatment. In contrast, anti-inflammatory treatment may have negative effects since

aggressive meningioma phenotypes appear to be associated with attenuated inflammatory markers here and in previous literature.<sup>12,15</sup>

The HOTAIR regulatory pathway was significantly affected by DEGs in the Ingenuity Pathway Analysis (Supplementary Material S4). We investigated DEGs downstream in the regulatory pathway, not HOTAIR expression. HOTAIR is a long noncoding RNA that modulates gene expression by interaction with chromatin remodeling complexes and specifically the PRC2 complex.<sup>40</sup> The PRC2 complex balances proliferation versus differentiation.<sup>41</sup> Atypical meningiomas exhibit upregulation of the catalytic subunit EZH2 of the PRC2 complex,<sup>42</sup> a finding reproduced in grade III meningiomas in our data. Deregulation in either direction can have an oncogenic effect and a possible effect on the threshold of transcriptional activation of genes controlling proliferation such as *CDKN2A*, a known biomarker in meningioma.<sup>6,43</sup> *E2F* is a part of the repressive DREAM complex regulating cell cycle,<sup>44</sup> and loss of the repressive function characterizes aggressive meningiomas with aggressive phenotypes.<sup>8</sup>

Patients with secondary malignant meningioma had higher expression (Supplementary Material S3) of *MYBL2*,<sup>10</sup> among others, in the first sample from a grade III meningioma compared with the last premalignant grade I or II meningioma sample, while *P2RY12*<sup>34</sup> and *FGL2*<sup>37</sup> were downregulated, possibly enabling or marking the malignant switch.

Within the grade III meningiomas, we found no difference in gene expression between the first grade III meningiomas from patients with primary (n = 27) and secondary (n = 24) malignant meningiomas. Data on whether overall survival differs between primary and secondary grade III tumors are contradictory,<sup>16,45</sup> and molecular or phenotypic differences remain unknown. Anaplastic versus rhabdoid/papillary seemed to cluster; however, the q value was 0.31 (Supplementary Material S7). The gene expression profile did not differentiate tumors with rhabdoid/papillary features with and without concomitant anaplasia or high mitotic index, although the material was small.

### Limitations and Strengths

Our study was limited by the number of malignant meningiomas and the retrospective design. Pathological diagnoses were validated to agree with 2016 WHO grading, but we could not completely exclude previous misclassification with omission of eligible cases. Our benign controls had a 5-year follow-up; the criteria strongly suggested a benign phenotype but did not completely rule out later recurrence. We did not have data on precise steroid dosages before surgery, which could have influenced the neuroinflammation signature. We had no reason, however, to suspect a large dosage discrepancy between the two groups. Clinical data were used for characterization of the contrasting phenotypes in the cohort (Table 1), but in-depth clinical data from the patients with grade III meningiomas were not compared with gene expression for statistical reasons with our study design. The risk of false-positive findings would be unacceptably high, with additional clinical outcomes and more granular phenotypes. We preselected the four most important analyses according to hypotheses and thus did not perform an exploratory investigation that would have required a validation cohort. The retrospective nature of data also limited causal interpretations of gene expression changes or patterns in association with previous radiotherapy, outcome, or

survival. A targeted gene expression panel with a neuroinflammatory focus was chosen as 1) a predefined set of genes and hypotheses minimized the statistical risk of false-positive findings, 2) the sample quality was not expected to support a full transcriptome analysis with a median RIN of 2.3, and 3) we defined a need to increase knowledge of neuroinflammatory genes in contrasting phenotypes of meningioma. We did not analyze protein synthesis that would have resulted from upregulated mRNA transcripts. Immunohistochemical analysis is warranted to localize gene products and quantitative analyses such as Western blot for quantification; moreover, proteomics can depict relevant protein expression. Logical next steps are targeted analysis of immunohistochemical expression and quantification of, for example, *FOXMI* in meningioma and more exploratory studies of proteins with proteomics methodologies.

Despite its limitations, the study had unusual strengths. The study included samples from several stages of disease from an unselected population of meningioma patients treated in Eastern Denmark, and the sample size was comparatively large for malignant meningiomas. It was still possible to obtain tissues from repeated surgeries during malignant transformation, and we had detailed clinical information from malignant meningiomas and benign controls. The cohort was thereby uniquely suitable to study gene expression signatures of malignant phenotypes and malignant transformation over time in a hypothesis-driven manner within the preplanned analyses 1–4. Because of this study design, we refrained from dividing patients into discovery and validation cohorts and employed all data for testing the primary statistical hypotheses. Prospective validation of premalignant and malignant gene signatures is needed, preferably across multiple institutions, and the causal relation between upregulated transcripts and malignant transformation can be analyzed in experimental settings such as murine knockout models.

## Conclusions

Our results from an unselected population of 51 patients with WHO grade III meningiomas showed that premalignant WHO grade I meningiomas had a gene expression signature different from that of benign WHO grade I meningiomas and similar to WHO grade III meningiomas years before histopathological transformation to a malignant phenotype. Moreover, we found different neuroinflammatory profiles in benign and malignant meningiomas, particularly among RNA transcripts involved in microglia regulation. Taken together, results from our targeted gene expression analyses show novel features that can allow early detection of malignant phenotypes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

A.D.M. and T.M. received a grant from The Danish Cancer Society (R278-A16459). A.D.M. received a grant from The Research Fund of Rigshospitalet, Copenhagen University Hospital. T.M. is funded by The Lundbeck Foundation (R266-2017-4029). The Bio- and GenomeBank Denmark is acknowledged for biological material and for data regarding handling and storage. We thank the laboratory scientists in the Department of Pathology, Rigshospitalet, Copenhagen, for their technical expertise and help.

## ABBREVIATIONS

<b>DEG</b>	differentially expressed gene
<b>DV<sub>300</sub></b>	percentage of RNA fragments > 300 nucleotides
<b>PBI</b>	probabilistic index
<b>RIN</b>	RNA integrity number
<b>TAM</b>	tumor-associated macrophage
<b>UHCL</b>	unsupervised hierarchical clustering


## References

- Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. *Neuro Oncol.* 2018;20(suppl 4):iv1–iv86. [PubMed: 30445539]
- Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO Classification of Tumours of the Central Nervous System 4th ed. International Agency for Research on Cancer, World Health Organization; 2016.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23(8):1231–1251. [PubMed: 34185076]
- Maier AD, Stenman A, Svahn F, et al. TERT promoter mutations in primary and secondary WHO grade III meningioma. *Brain Pathol.* 2021;31(1):61–69. [PubMed: 32805769]
- Mirian C, Duun-Henriksen AK, Juratli T, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. *J Neurol Neurosurg Psychiatry.* 2020;91(4):378–387. [PubMed: 32041819]
- Sievers P, Hielscher T, Schrimpf D, et al. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathol.* 2020;140(3):409–413. [PubMed: 32642869]
- Fountain DM, Young AMH, Santarius T. Malignant meningiomas. *Handb Clin Neurol* 2020;170:245–250. [PubMed: 32586496]
- Patel AJ, Wan YW, Al-Ouran R, et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. *Proc Natl Acad Sci U S A.* 2019;116(43):21715–21726. [PubMed: 31591222]
- Collord G, Tarpey P, Kurbatova N, et al. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. *Sci Rep.* 2018;8(1):13537. [PubMed: 30202034]
- Chen WC, Vasudevan HN, Choudhury A, et al. A prognostic gene-expression signature and risk score for meningioma recurrence after resection. *Neurosurgery* 2020;88(1):202–210. [PubMed: 32860417]
- Proctor DT, Huang J, Lama S, Albakr A, Van Marle G, Sutherland GR. Tumor-associated macrophage infiltration in meningioma. *Neurooncol Adv* 2019;1(1):vdz018. [PubMed: 32642654]
- Borch JDS, Haslund-Vinding J, Vilhardt F, Maier AD, Mathiesen T. Meningioma—brain crosstalk: a scoping review. *Cancers (Basel)* 2021;13(17):4267. [PubMed: 34503077]
- Nassiri F, Liu J, Patil V, et al. A clinically applicable integrative molecular classification of meningiomas. *Nature.* 2021;597(7874):119–125. [PubMed: 34433969]
- Yeung J, Yaghoobi V, Miyagishima D, et al. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. *Neuro Oncol.* 2021;23(11):1922–1935. [PubMed: 33914067]
- Haslund-Vinding J, Møller JR, Ziebell M, Vilhardt F, Mathiesen T. The role of systemic inflammatory cells in meningiomas. *Neurosurg Rev* 2022;45(2):1205–1215. [PubMed: 34716512]

16. Maier AD, Mirian C, Haslund-Vinding J, et al. Granular clinical history and outcome in 51 patients with primary and secondary malignant meningioma. *J Neurosurg*. Published online March 11, 2022. doi:10.3171/2022.1.JNS212723
17. Vasudevan HN, Braunstein SE, Phillips JJ, et al. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. *Cell Rep*. 2018;22(13):3672–3683. [PubMed: 29590631]
18. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Accessed August 3, 2022. <https://www.r-project.org/>
19. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523–530. [PubMed: 24336805]
20. Hansson CM, Buckley PG, Grigelioniene G, et al. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. *BMC Genomics*. 2007;8(1):16. [PubMed: 17222329]
21. Sahn F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncol* 2017;18(5): 682–694. [PubMed: 28314689]
22. Mirian C, Skyрман S, Bartek J Jr, et al. The Ki-67 Proliferation index as a marker of time to recurrence in intracranial meningioma. *Neurosurgery* 2020;87(6):1289–1298. [PubMed: 32614441]
23. Daniela Maier A, Brøchner CB, Bartek J Jr, et al. Mitotic and proliferative indices in WHO Grade III meningioma. *Cancers (Basel)* 2020;12(11):3351. [PubMed: 33198268]
24. Viaene AN, Zhang B, Martinez-Lage M, et al. Transcriptome signatures associated with meningioma progression. *Acta Neuropathol Commun*. 2019;7(1):67. [PubMed: 31039818]
25. Kim H, Park KJ, Ryu BK, et al. Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression. *Neuropathol Appl Neurobiol* 2020;46(2):125–141. [PubMed: 31179553]
26. Liao GB, Li XZ, Zeng S, et al. Regulation of the master regulator FOXM1 in cancer. *Cell Commun Signal*. 2018;16(1):57. [PubMed: 30208972]
27. Chesnokov MS, Halasi M, Borhani S, et al. Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. *Cell Death Dis* 2021;12(7):704. [PubMed: 34262016]
28. Qiu Z, Oleinick NL, Zhang J. ATR/CHK1 inhibitors and cancer therapy. *Radiother Oncol*. 2018;126(3):450–464. [PubMed: 29054375]
29. Lee JM, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. *Lancet Oncol* 2018;19(2): 207–215. [PubMed: 29361470]
30. Haynes SE, Hoppeler G, Yang G, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci*. 2006;9(12):1512–1519. [PubMed: 17115040]
31. Zujovic V, Benavides J, Vigé X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. *Glia*. 2000;29(4):305–315. [PubMed: 10652441]
32. Li G, Hattermann K, Mentlein R, Mehdorn HM, Held-Feindt J. The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas. *Oncol Rep*. 2013;29(2):563–570. [PubMed: 23229614]
33. Keane L, Cheray M, Blomgren K, Joseph B. Multifaceted microglia—key players in primary brain tumour heterogeneity. *Nat Rev Neurol*. 2021;17(4):243–259. [PubMed: 33692572]
34. Zhu C, Kros JM, van der Weiden M, Zheng P, Cheng C, Mustafa DA. Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. *Acta Neuropathol Commun*. 2017;5(1):4. [PubMed: 28073370]
35. Hu J, Yan J, Rao G, et al. The duality of Fgl2-secreted immune checkpoint regulator versus membrane-associated procoagulant: therapeutic potential and implications. *Int Rev Immunol*. 2016;35(4):325–339. [PubMed: 25259408]


36. Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. *Oncogene*. 2005;24(41):6323–6327. [PubMed: 16007200]
37. Yan J, Kong LY, Hu J, et al. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. *J Natl Cancer Inst*. 2015;107(8):1–10.
38. Yan J, Zhao Q, Gabrusiewicz K, et al. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. *Nat Commun*. 2019;10(1):448. [PubMed: 30683885]
39. Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. *Cancer Cell*. 2019;35(4):588–602.e10. [PubMed: 30930117]
40. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature*. 2010;464(7291):1071–1076. [PubMed: 20393566]
41. Laugesen A, Højfeldt JW, Helin K. Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer. *Cold Spring Harb Perspect Med*. 2016;6(9):1–20.
42. Harmancı AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. *Nat Commun*. 2017;8:14433. [PubMed: 28195122]
43. Williams EA, Santagata S, Wakimoto H, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. *Acta Neuropathol Commun*. 2020;8(1):171. [PubMed: 33087175]
44. Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. *Nat Rev Cancer*. 2013;13(8):585–595. [PubMed: 23842645]
45. Peyre M, Gauchotte G, Giry M, et al. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. *Neuro Oncol*. 2018;20(8):1113–1121 [PubMed: 29216385]

**Patients with WHO grade III meningioma, n = 51, n tumors = 139**




**FIG. 1.**

Overview of patients and meningiomas and the four pre hoc planned comparisons. Analysis 1 compares the first (earliest presenting) grade III meningiomas (n = 51) with benign grade I meningiomas from controls (n = 51). Analysis 2 compares the first premalignant grade I meningioma (n = 9) with benign grade I meningioma from controls (n = 51). Analysis 3 comprises the first grade III meningioma from patients with primary grade III meningioma (n = 27) compared with the first grade III meningiomas from patients with secondary malignant meningiomas (n = 24). Analysis 4 is within patients with secondary grade III meningioma: the last premalignant tumor (grade I or II) compared with the first grade III meningioma within individual patients.




**FIG. 2.** PBIs, p values, and adjusted p values for analyses 1 (left) and 2 (right). **Left:** In analysis 1 the first grade III meningiomas (n = 51) were compared with benign grade I meningiomas from controls (n = 51). The genes are ranked by magnitude of PBI, and the top 50 of the 429 genes (adjusted p < 0.05) are shown. **Right:** In analysis 2, the first pre-malignant grade I meningiomas (n = 9) were compared to benign grade I meningiomas (n = 51). Genes are ranked according to adjusted p value, and 37 genes have an adjusted p < 0.05 (border marked with a dotted red horizontal line). Adj. = adjusted; gr. = grade.






**FIG. 3.** Heatmap and UHCL of DEGs from t-tests comparing mRNA expression between 51 WHO grade III meningiomas (*orange*) and 51 WHO grade I meningiomas from controls (*blue*). The analysis yielded 78 DEGs out of 787 investigated genes with a > 2-fold change in gene expression,  $p < 0.05$ , and  $q = 0.08$  (36 upregulated in grade III [*yellow*] and 42 downregulated in grade III [*blue*]).



**FIG. 4.** Volcano plot of DEGs from t-tests comparing mRNA expression between 51 WHO grade III meningiomas and 51 WHO grade I meningiomas from controls. *Dashed lines* indicate cutoff values for differential expression. Annotated genes have a log<sub>2</sub> fold change > 1.8.



**FIG. 5.** Heatmap and UHCL of DEGs from t-tests comparing mRNA expression between 9 premalignant grade I meningiomas (*orange*) and 51 benign grade I meningiomas (*gray*) (analysis 2). The analysis yielded 21 DEGs out of 787 investigated genes with a > 2-fold change in gene expression, p value < 0.05, and q = 0.20 (17 upregulated in premalignant grade I [*yellow*] and 4 downregulated in premalignant grade I [*blue*]).

**TABLE 1.**

Clinical characteristics of patients with WHO grade III meningioma and benign controls

	<b>Patients w/ Grade III Meningioma (n = 51)*</b>	<b>Benign Controls (n = 51)</b>
Surgeries, n	151	51
Age at op, median (range)	61 (10–87)	60 (29–85)
Male sex, n (%)	25 (49.0)	24 (47.1)
Skull base location, n (%)	9 (17.6)	8 (15.7)
Age of sample in yrs, median (range) <sup>†</sup>	8.2 (0.4–24.6)	10.8 (6.3–21.2)
Histology, n (%)		
Anaplastic	42 (82.4)	0 (0)
Papillary features	4 (7.8)	0 (0)
Rhabdoid features	5 (9.8)	0 (0)
Meningothelial, fibrous, transitional	0 (0)	50 (98.0)
Angiomatous	0 (0)	1 (2.0)

\* Data are based on the first (earliest presenting) WHO grade III meningioma.

<sup>†</sup> Sample age was calculated from last follow-up date.

Genes sorted by neuroinflammatory pathways in analysis 1 comparing WHO grade III meningiomas with WHO grade I meningiomas from benign controls

**TABLE 2.**

Pathway (annotated by NanoString)	Genes Annotated to Pathway (n)	DEG w/in Pathway*	Genes†
Microglia‡	187	28	Top 5 downregulated: <i>P2RY12, NPNT, CX3CR1, JAM2, IGF1</i> Top 5 upregulated: <i>RRM2, SPP1, LMNB1, TPD52, SLC2A1</i>
Cytokine‡	117	8	Downregulated: <i>CSFR1, TNFRSF25, CX3CR1, KIT, IL1R1</i> Upregulated: <i>BIRC3, NEFL</i>
Inflammatory signaling	102	3	Downregulated: <i>CD74, FGL2</i> Upregulated: <i>BIRC3</i>
Innate immune system	144	2	Downregulated: <i>MAPK10</i> Upregulated: <i>BIRC3</i>
Oligodendrocyte	27	5	Downregulated: <i>ENPP6, GSN</i> Upregulated: <i>MAG, MOBP, MYRF</i>
Adaptive immune response	130	9	Downregulated: <i>KIT, BLNK, CD74, MAPK10, CTSF, SIGLEC8</i> Upregulated: <i>NEFL, KIF2C, TUBB4A</i>
Astrocyte	55	7	Downregulated: <i>C4A, ENTPD2</i> Upregulated: <i>SLC6A1, SERPIN3A, CP, SOX9, PTX3</i>
Neuron	81	5	Downregulated: None Upregulated: <i>TUBB4A, PPF1A4, SLC6A1, TPD52, NEFL</i>

\* For all analyses,  $q < 0.09$  and  $> 2$ -fold change in gene expression.

† Up-/downregulation in grade III meningiomas compared with grade I meningiomas from benign controls.

‡ Heatmaps of the microglia- and cytokine-associated DEGs in analysis 1 can be seen in Supplementary Material S3.